The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
CARDIFF ONCOLOGY INC | COM | 14147L108 | 9,200 | 1,383,500 | SH | SOLE | 1 | 1,383,500 | 0 | 0 | |
COINBASE GLOBAL INC | COM CL A | 19260Q107 | 10,132 | 40,000 | SH | SOLE | 1 | 40,000 | 0 | 0 | |
CRISPR THERAPEUTICS AG | NAMEN AKT | H17182108 | 3,238 | 20,000 | SH | SOLE | 1 | 20,000 | 0 | 0 | |
CUE BIOPHARMA INC | COM | 22978P106 | 17,323 | 1,486,986 | SH | SOLE | 1 | 1,486,986 | 0 | 0 | |
DIAMEDICA THERAPEUTICS INC | COM NEW | 25253X207 | 906 | 203,641 | SH | SOLE | 1 | 203,641 | 0 | 0 | |
HIMAX TECHNOLOGIES INC | SPONSORED ADR | 43289P106 | 3,332 | 200,000 | SH | SOLE | 1 | 200,000 | 0 | 0 | |
IRIDIUM COMMUNICATIONS INC | COM | 46269C102 | 3,199 | 80,000 | SH | SOLE | 1 | 80,000 | 0 | 0 | |
KRATOS DEFENSE & SEC SOLUTIO | COM NEW | 50077B207 | 7,856 | 275,738 | SH | SOLE | 1 | 275,738 | 0 | 0 | |
LANTERN PHARMA INC | COM | 51654W101 | 9,583 | 656,364 | SH | SOLE | 1 | 656,364 | 0 | 0 | |
MAXAR TECHNOLOGIES INC | COM | 57778K105 | 76,660 | 1,920,333 | SH | SOLE | 1 | 1,920,333 | 0 | 0 | |
MP MATERIALS CORP | COM CL A | 553368101 | 4,055 | 110,000 | SH | SOLE | 1 | 110,000 | 0 | 0 | |
QUANTUMSCAPE CORP | COM CL A | 74767V109 | 9,870 | 337,316 | SH | SOLE | 1 | 337,316 | 0 | 0 | |
REATA PHARMACEUTICALS INC | CL A | 75615P103 | 10,065 | 71,115 | SH | SOLE | 1 | 71,115 | 0 | 0 | |
REPLIMUNE GROUP INC | COM | 76029N106 | 17,284 | 449,879 | SH | SOLE | 1 | 449,879 | 0 | 0 | |
ROBLOX CORP | CL A | 771049103 | 2,699 | 30,000 | SH | SOLE | 1 | 30,000 | 0 | 0 |